{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}],"title":"No response detected"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Hematologic disease response"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Hematologic disease response evaluated at Day 28 following CART-cell infusion, as overall response rate (ORR), stringent complete response (sCR), CR, very good partial response (VGPR) and partial response (PR).","groups":[{"description":"Patients were scheduled to receive a single intravenous (iv) infusion of CD44v6.CAR-transduced autologous lymphocytes at day 0, after lymphodepleting chemotherapy with cyclophosphamide iv (500 mg/m2) and fludarabine iv (30 mg/m2) performed daily from day -5 to day -3\n\nThe dose of iv infused MLM-CAR44.1 T-cells is:\n\nPHASE I: 0.5x10E6/Kg or 1x10E6/Kg or 2x10E6/Kg according to the BOIN design. PHASE IIa: a dose of MLM-CAR44.1 T-cells corresponding to the maximum tolerated dose (MTD).","id":"OG000","title":"MLM-CAR44.1 T-cells Infusion"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Hematologic disease response of the two treated patients was evaluated at Day 28 following CART-cell infusion. Both patients showed a progressive disease (PD) and no sign of response.","reportingStatus":"POSTED","timeFrame":"1 and 3 months following T-cell infusion, assessed as day 0","title":"Phase I: Hematologic Disease Response to MLM-CAR44.1 T-cells in MM","type":"SECONDARY","unitOfMeasure":"Participants"}